Perspectives on the Management of Vascular Depression
Publication: American Journal of Psychiatry
“Mr. A,” an 80-year-old married man, presents for his first psychiatric evaluation. He arrives punctually, carrying a manila folder containing documents summarizing his medication history and previous surgical procedures. He reports that this outpatient visit was initiated by a referral from his primary care physician after his wife expressed concern that her husband appeared to be depressed. Mr. A denies any previous mental health problems, history of psychotropic medication use, or history of therapy. He reports a period of bereavement after the death of his first wife at age 40 but states that he recovered over time without intervention. He remarried 17 years ago and describes his wife as supportive. He previously worked in an executive position that required substantial travel overseas. The development of angina on these trips ultimately resulted in the placement of multiple cardiac stents, and he retired 12 years ago because of health concerns. He has been less active since retirement, and he states that he has no hobbies. He reports that he still ruminates a great deal about events that occurred during his career.
When asked about depressive symptoms, Mr. A does not agree that he is depressed and questions the need for the referral. He admits to feeling socially detached, with a loss of interest and lack of motivation, and states, “I know that I should get out more, but I can’t ever get past the first step.” While he denies feeling overtly sad, he reports feeling irritable at times toward his family, which he finds troubling. According to his wife, Mr. A’s irritability is increasing in frequency and tends to arise without substantive provocation. His sleep is suboptimal, with frequent nighttime awakening due to nocturia, and difficulty returning to sleep. His appetite is adequate, but his weight has been slowly increasing, which he attributes to his sedentary lifestyle. He feels his memory is “okay,” noting that he occasionally has trouble finding the right word to use and that it is harder for him to focus when reading or paying the bills. He reports that his energy is low, and he blames this symptom on his cardiologist’s prescriptions for lisinopril and metoprolol. Overall, he ascribes his difficulties to increased medical problems over the past decade and a corresponding increase in medications. These medications now include atorvastatin for hypercholesterolemia and glipizide for type 2 diabetes in addition to antihypertensives, clopidogrel, and aspirin. He denies feelings of hopelessness and helplessness, but he reports that he sometimes feels discouraged at the change in his ability to function relative to his earlier years. He denies suicidal ideation but casually admits to worries that in the future he could become a burden if he experiences another serious cardiac event.
A comprehensive interview was conducted to assess not only Mr. A’s current symptoms but also factors contributing to his social isolation. During the interview, Mr. A identified some activities that he may take up, including a return to working out in a gym. He noted that when he was young, he was quite conscientious about attending a gym, but this activity was sidelined during his executive years. He was receptive to the idea of restarting a regular workout program and had a senior discount for a gym membership in his neighborhood. A comprehensive review of his sleep-wake cycle suggested that he tended to spend a lot of time at the computer in the evening, out of boredom. He was advised to reduce exposure to light in the evening and begin taking melatonin at bedtime to help stabilize his day-night cycle and increase the restfulness of his sleep. Additional management included the initiation of sertraline, at 25 mg every morning initially, increasing to 50 mg with a plan to further titrate the dosage if well tolerated and needed. He was instructed to focus on positive health behaviors, including resuming regular physical activity, engaging more with his wife’s community activities, and maintaining a healthy diet. He was advised to focus on finding meaningful activities, and he was cautioned to avoid the expectation that medications alone would resolve his symptoms. Mr. A’s wife actively supported the treatment plan, offering to provide assistance in observing his irritability, sleep, and daily activities. Over the following months, Mr. A was able to see improvement in his motivation and was able to resume some remodeling projects. Ultimately, he was able to maintain a regular gym schedule, which, together with melatonin, resulted in improved sleep and well-being.
The case presented here reflects the characteristic psychiatric symptoms of vascular depression and its impact on daily life. Below, we discuss the epidemiology, clinical features, and radiographic markers of vascular depression as well as how it may relate to risk for suicide in later life. Our intention for this summary is to help illustrate the clinical features of age-related vascular disease and how it affects depression and cognition. A range of treatment strategies are then described that may be beneficial for vascular depression and may provide insights on innovations in the approach to this condition.
Age-related vascular changes have long been observed to be related to depressive syndromes in later life. The insidious role of subcortical microvascular disease was recognized initially as a critical factor in the development of neurocognitive symptoms by Binswanger in 1894 (1), but the prominent role of depressive features in this condition did not become a major focus of study until many decades later (2). In the late 1990s, investigators studying late-life mood disorders proposed the concept of “vascular depression” as a research subtype of late-life unipolar depression (3). Two pivotal papers that spurred further studies of vascular depression focused, respectively, on clinically defined and MRI-defined criteria to operationalize its features (4, 5). Subsequent research testing the “vascular depression hypothesis” (6) leveraged improvements in neuroimaging methods, and the capacity of MRI-based diffusion tensor imaging to examine white matter integrity has allowed exploration of the relationship between damage to white matter and development and maintenance of depressive symptoms (7). Despite a large volume of research, vascular depression is not represented in the DSM-5 classification, an omission that may represent a missed opportunity to increase clinical recognition and clinically informed systematic study.
“Late-life depression” is diagnosed when a major depressive episode occurs in older adults, (3, 8). This is a heterogeneous group, including individuals with “early-onset” depression that arose in adolescence or early adulthood and those with “late-onset” depression, where the initial depressive episode occurs after ages 50–55. Like other variants of late-life depression, vascular depression has unique characteristics that distinguish it from early-onset depression. Notably, vascular depression frequently develops after ages 60–65 in the absence of a prior history of affective illness, and there is often no family history of affective disorder. Depression related to vascular aging does not follow a path of clearly delineated episodes with recovery, in the way early-onset depressive disorders do. In vascular depression, there is often a more persistent character to the mood and cognitive symptoms that may fluctuate over time, without discrete episodes. This insidious and often chronic course tends to delay the recognition and necessary assessments, sometimes considerably. Patients with vascular depression also may have less insight into their mood symptoms and may be less aware of and less comfortable with mental health services. A recent consensus report on vascular depression specified key symptoms of low energy, lack of insight, anhedonia, deficits in self-initiation, psychomotor retardation, and reduced processing speed (9). As in the case of Mr. A in the vignette, patients with vascular depression may not perceive themselves to have a depressive disorder. Initial evaluation often occurs at the insistence of family members who observe a change in daily function and perhaps an increase in irritability or apathy.
Epidemiology
Vascular depression is not a distinct diagnosis in DSM-5, and it has different operational definitions in various classifications, leading to variance among estimates of its frequency. One U.S. study (10) used a national probability sample of 16,423 adults to examine the population prevalence using survey assessments. Vascular depression was defined by applying DSM-IV criteria for an episode of major depressive disorder within the preceding 12 months in adults age 50 or older with cardiovascular or cerebrovascular disease or major cardiovascular risk factors. The prevalence of major depression without vascular disease was 12.2%, and the population prevalence of vascular depression was 3.4%. Among respondents affected with depression, more than one-fifth (22.1%) of those with a lifetime history of major depressive episodes met study criteria for vascular depression. These rates were higher than those found in a Korean two-stage epidemiological study of older adults (age 65 or older) using an MRI-based definition of vascular depression (11). In that population-based survey of 783 participants, the prevalence of major depression without MRI-defined vascular disease was 2.36%, and the prevalence of major depression with MRI-defined vascular disease was 2.40%. Notably, rates of MRI-defined vascular depression increased with advanced age, so in the cohort age 75 or older with a diagnosis of major depression, all patients met radiographic criteria for vascular depression.
Cognitive Features Affecting Clinical Management
Vascular depression is often characterized as a disorder of executive dysfunction, including difficulty with task completion and decision making, both of which may increase the likelihood of experiencing irritability and social withdrawal. Additional cognitive features of vascular depression include slowed speed of information processing and impairments in concentration and attention. It is not uncommon for these cognitive complaints, rather than depressive symptoms, to be the trigger for a clinical evaluation. Given the common nature of cognitive concerns in older adults, patients and families may be more amenable to engaging in the assessment process when discussing problems with attention, concentration, reasoning, and memory. In contrast, discussing one’s mood or emotions may be more difficult for an older patient. When the treatment plan and assessment are couched in seeking to improve attention, concentration, planning, and engagement in life, the therapeutic relationship can be enhanced substantially. Moreover, an awareness of the type of cognitive deficiencies associated with vascular depression can help in finding ways to increase social engagement and understand some of the limitations that patients may be experiencing. This approach is at the heart of problem-solving therapy, a form of cognitive-behavioral therapy (CBT) that has been adapted for older depressed patients with executive impairment (12, 13). Given the predominance of difficulties with psychomotor slowing, poor initiation of thought and movement, and reduced processing speed, as well as relative impairment in insight into mood symptoms, it is not uncommon for the depressive symptoms associated with vascular depression to fall short of the DSM criteria for major depressive disorder. However, in older adults, even subthreshold depressive disorders can have a substantial impact on functional status, quality of life, and mortality (14).
Along these lines, it has also been recognized that depressive symptoms may at times be a less prominent component within vascular depression, which may be characterized as a “depression-executive dysfunction syndrome,” as proposed by Alexopoulos and colleagues (15). This conceptualization focuses on executive and information processing deficits often observed in late-life depression, with an emphasis on these deficits in the diagnostic evaluation. The depression-executive dysfunction syndrome is associated with a range of clinical symptoms, including reduced fluency, impaired visual naming, psychomotor retardation, loss of interest in activities, and paranoia. In contrast, other depressive symptoms were comparatively milder. Notably, among depressed patients without the depression-executive dysfunction syndrome, depressive symptoms appeared to have less of a disabling effect than in patients with executive dysfunction. Consequently, vascular depression and depression-executive dysfunction syndrome may be conceptualized along the same spectrum of illness, with cognitive features being particularly pronounced in the latter. Depending on methods used for diagnostic evaluation, many patients may meet criteria for both disorders, reflecting the considerable clinical and diagnostic overlap between the two.
Given the prominent cognitive features in both depression-executive dysfunction syndrome and vascular depression, it is unsurprising that depressed elders are at increased risk for progression to a major neurocognitive disorder. Multiple studies have examined populations with late-life depression (of which vascular depression is one subtype) and demonstrated an increased longitudinal risk for dementia. A meta-analysis examining 23 population-based prospective studies found that late-life depression was associated with a twofold increased risk for dementia of any type and that the increased risk for vascular dementia exceeded that for dementia of the Alzheimer’s type (16). A parallel longitudinal study of late-life depression further demonstrated that white matter hyperintensity volume was independently associated with time to dementia (17).
This complex interplay between late-life mood symptoms and cognitive deficits has been difficult to capture within diagnostic nosology, particularly if both are related to cerebrovascular pathology. However, the new criteria for the cognitive disorders in DSM-5, which include the classification of “mild” neurocognitive disorder, now permit the specification of cognitive symptoms as being due to vascular disease when they have passed the threshold of severity to qualify for mild neurocognitive disorder, in the same manner that “mild cognitive impairment” was previously employed to represent the transition phase of risk for a dementia syndrome (18). Given that cognitive symptoms other than concentration deficits are not included in the DSM-5 diagnostic criteria for major depressive disorder, we propose that mood and cognitive symptoms be evaluated and diagnosed separately according to the respective criteria. For example, if criteria are met for both mild vascular neurocognitive disorder and a DSM-5 mood disorder diagnosis such as major depressive disorder, then both disorders should be recognized, for the greatest diagnostic clarity.
Clinical Assessment and Radiographic Markers
The assessment for vascular depression ideally includes not only a review of vascular risk factors and history of vascular disease but also evidence demonstrating subcortical white matter disease. Such findings are observed on an MRI brain scan as periventricular or deep white matter hyperintensities. In the clinical setting, it is not uncommon for these findings to be noted within the narrative text of the radiology report, with the overall impression often reading as “unremarkable for age.” This may lead to a reduced awareness, clinically, of the potential relationships of these findings with the clinical syndrome. For example, one study of healthy community-dwelling adults ages 44–48 reported that white matter hyperintensities were found in 50.9% of individuals (7). However, in most cases the severity of white matter hyperintensities is mild, and MRI-based definitions of vascular depression require a minimum threshold of white matter hyperintensity severity for diagnosis (19).
Given the overwhelming frequency with which clinical radiologists see white matter hyperintensities, it may be difficult for them to raise clinical concerns unless the white matter changes are particularly severe or there is a clinical background describing cognitive changes or motor impairment. The burden may fall on the psychiatrist to bring together imaging information with the clinical features of vascular depression to help educate individual patients as to the range of symptoms experienced, their underlying causes, and the rationale for treatment. Despite the lack of clarity in general clinical practice regarding the relevance of white matter hyperintensities on MRI scans, numerous neuroimaging studies have demonstrated that a greater burden of white matter hyperintensities correlates with poor treatment response (9, 20). Consequently, the best approach for incorporating white matter hyperintensities into clinical decision making may be to consider the presence of white matter hyperintensities as a risk factor for symptoms of vascular depression as well as potentially a prognostic factor when evidence of particularly severe white matter hyperintensities is observed in the context of depression. However, the ability to quantify their precise impact on risk and outcome remains to be clarified in future research, given the multiple factors that interact in late-life disorders. Data from relatively new techniques, such as diffusion tensor imaging, which utilizes fractional anisotropy as a more sensitive measure of white matter degradation, may offer new ways to better understand white matter changes in relation to depression, although studies to date remain mixed.
Treatment Issues
Suicide Risk
As suicide risk increases in later life, it is important to consider how the presence of vascular depression may affect this risk. While there is no clear evidence to date linking vascular depression specifically to suicide mortality, there is evidence that all-cause mortality is greater in persons with vascular depression. The higher mortality risk has been attributed to accelerated frailty, general morbidity, and cardiac death (18, 21). Recent mortality data from the U.S. Census Bureau highlight a concern about increasing “deaths of despair” in middle-age individuals, relating to both suicide and “poisonings” associated with complaints of poor health (21, 22). A study examining suicide risk factors using data from the Veterans Health Administration (VHA) system (23) observed that chronic pain, sleep impairment, and traumatic brain injury were associated with a greater suicide risk, attesting to the impact of medical comorbidity. While the study did not directly compare risk between younger and older veterans, the impact of medical comorbidity is an important addressable risk factor that is highly relevant to older adults with depression. A separate VHA study similarly observed that older veterans who died by suicide were more likely to have had medical health problems (24). It further noted that nearly all the elderly decedents used firearms. A noteworthy study used data from the National Violent Death Reporting System for the years 2005–2014 to identify 16,924 suicide decedents over age 65 (25). The study noted that “physical health problems were recorded as a suicide precipitant for 50% of the older decedents.” For those decedents who disclosed intent, concerns centered on pain, cancer, fear of dementia-related decline, fear of burdening others, unwillingness to live in a nursing home, and loss of independence. Finally, the cognitive symptoms of late-life depression also increase risk. Older depressed patients with executive impairment such as poor cognitive control are at increased risk for suicide attempt. Of note, problem-solving therapy can reduce suicidal ideation in older depressed adults with executive dysfunction (13).
Treatment Issues
Management
Vascular depression not only increases the likelihood of poor response to antidepressant treatment and persistent depressive symptoms but also may contribute to poor self-management of medical comorbidities and greater impairments in daily function (26, 27). There may also be cumulative disability associated with impaired sleep, chronic pain, and use of analgesic medications, as well as complex conditions such as peripheral neuropathy and impaired mobility, all of which add to the likelihood of poor outcomes in vascular depression. Response to treatment is significantly attenuated in the context of vascular depression (9), so typical treatment strategies are often unsatisfactory and do not result in full remission of depressive symptoms. For example, one of the few randomized controlled pharmacological treatment trials of vascular depression observed the low remission rate of 33% (28), even with careful titration of the selective serotonin reuptake inhibitor (SSRI) sertraline over a 12-week period. The study highlighted the interrelationships between white matter disease and depression outcome by demonstrating that both pretreatment neuropsychological function and severity of white matter hyperintensities independently predicted treatment response over the course of the trial. Despite the poor response in this trial, there is still value in antidepressant therapy for this patient population, as even a small reduction in symptoms may enhance quality of life. Furthermore, there is intriguing evidence that SSRI use may be associated with improved neural resilience in relevant brain regions, such as the hippocampus (29, 30), as well as novel evidence of a potential reduction in amyloid production, which may have relevance in reducing cognitive decline (31).
The poor response to antidepressants in vascular depression has been well documented (9). Yet there may be potential insights from studies suggesting that cognition may be targeted by antidepressants independently of mood symptoms in the context of major depression, although vascular depression has not specifically been studied (32). Among these studies, several have reported that vortioxetine, a multimodal serotonergic compound, was associated with improvement in executive function and other cognitive domains (33–35). However, while some of these studies included older adults, the safety profile for elderly adults with vascular depression has not yet been clarified. Thus, while new pharmacologic strategies offer hope for the future, an approach that incorporates wellness and general health maintenance will likely remain essential to achieving optimal outcomes. This approach includes attending to regular sleep, exercise, healthy diet, and medication adherence to minimize the impact of hypercholesterolemia, hypertension, and glucose intolerance.
Addressing sleep may offer an important opportunity to provide some relief for older adults with depression early in the course of treatment while waiting for an eventual response to therapy or antidepressant treatment. Kay et al. (36) observed that impaired sleep may increase risk for suicidal behavior in middle-aged and older adults even after adjusting for other risk factors. Furthermore, the Established Populations for Epidemiologic Studies of the Elderly study of 14,456 older adults in the community demonstrated that poor subjective sleep quality was associated with an increase in risk of death by suicide over a 10-year period. Because of concerns regarding side effects associated with hypnotic use in the elderly as well as a potential for an independent suicide risk incurred by hypnotic medications (37), management should focus on lifestyle and general health issues while attending to risk of sleep disorders common in later life, such as sleep apnea. Sleep impairment may be related to reduced endogenous melatonin production with increasing age. Furthermore, given emerging evidence that melatonin may be advantageous for age-related brain changes, melatonin supplementation may be a useful strategy to reduce symptom burden in the context of vascular depression (38). A systematic review that synthesized 16 studies of the use of melatonin in older adults noted that low doses are recommended; dosing at no more than 1–2 mg of immediate-release melatonin is optimal, and it should be administered approximately 1 hour before bedtime for disturbed sleep in this population (39).
Given high rates of polypharmacy and limited efficacy of psychotropic treatments for lowering depression burden in vascular depression, psychotherapeutic approaches to treatment have also been explored. To address sleep disturbance, CBT for insomnia may be a useful tool. While CBT for insomnia was initially demonstrated as efficacious for primary insomnia (40), it is also effective when the insomnia is comorbid with a medical or psychiatric condition (41). Current psychotherapies often used in conjunction with other treatments to manage vascular depression have been developed to address symptoms that are more often associated with late-life onset and cognitive deficits. For example, executive dysfunction, which includes impairment in task completion and difficulty with decision making, may be addressed with skills developed through problem-solving therapy or problem adaptation therapy (42), a variant of problem-focused psychotherapy. Problem adaptation therapy is consistent with the process model of emotion regulation (12, 43), but it uses an adapted approach to these emotion and behavioral psychotherapies through distinct features, including home delivery, addressing compensatory strategies, environmental adaptations, and caregiver participation. Other related strategies may partly circumvent cognitive skills and rely on behavioral strategies and interpersonal therapy to help boost mood through caregiver engagement. Evidence-based psychotherapies have been shown to be superior to other strategies that have been used with older adults in the past, such as supportive therapy, which relies solely on empathic support without specific methods to address the needs of patients with late-onset depression, such as vascular depression. Psychotherapies such as problem adaptation therapy and problem-solving therapy as well as other behavioral and interpersonal psychotherapeutic strategies aimed at improving sleep hygiene or behavioral activation can be a flexible component to long-term treatment plans.
An additional treatment option that may bear further exploration for patients with refractory vascular depression is repetitive transcranial magnetic stimulation (rTMS). A study by Jorge and colleagues (44) examined rTMS for patients with vascular depression who had been unresponsive to at least one course of treatment with an antidepressant medication. Participants received active or sham rTMS to the left dorsolateral prefrontal cortex. While there was a significant improvement in symptoms in the active treatment group compared with the sham treatment group, the depression remission rate remained modest at 27% in the active treatment group. However, it is notable that remission was achieved in patients previously unresponsive to antidepressant medication. The study also found that improvement in depressive symptoms was negatively correlated with age, which is consistent with other treatment studies of vascular depression. Additionally, for patients with treatment-resistant or severe depression, the use of ECT is an important means of achieving remission (45). A recent study examining vascular risk factors in elderly inpatients receiving antidepressant management or ECT (46) found that ECT was significantly more effective than medications in achieving remission in elderly inpatients with depression. Furthermore, remission from depression was not influenced by the vascular risk factor burden.
Summary: Clinical Pearls
•
The presenting features of vascular depression may involve poor motivation and slowed information processing as opposed to traditional mood complaints.
•
Although there is not currently an indication to obtain neuroimaging, when records are available, the assessment includes reviewing MRI reports for findings of deep white matter and periventricular hyperintensities as well as subcortical gray matter lesions.
•
Treatment planning should recognize that there may be a modest response to antidepressants and that other treatments, such as problem-solving therapy, may offer additional benefit.
•
Sleep hygiene may be important, and the patient may benefit from treatment with low-dose melatonin if indicated.
•
Management should include active support for the patient to reduce obesity, hypertension, hyperlipidemia, and glucose intolerance and to engage in appropriate dietary and exercise strategies to reduce vascular risk.
References
1.
Mathers SE, Chambers BR, Merory JR, et al: Subcortical arteriosclerotic encephalopathy: Binswanger’s disease. Clin Exp Neurol 1987; 23:67–70
2.
Venna N, Mogocsi S, Jay M, et al: Reversible depression in Binswanger’s disease. J Clin Psychiatry 1988; 49:23–26
3.
Andreescu C, Reynolds CF 3rd: Late-life depression: evidence-based treatment and promising new directions for research and clinical practice. Psychiatr Clin North Am 2011; 34:335–355
4.
Alexopoulos GS, Meyers BS, Young RC, et al: Clinically defined vascular depression. Am J Psychiatry 1997; 154:562–565
5.
Krishnan KR, Hays JC, Blazer DG: MRI-defined vascular depression. Am J Psychiatry 1997; 154:497–501
6.
Alexopoulos GS, Meyers BS, Young RC, et al: “Vascular depression” hypothesis. Arch Gen Psychiatry 1997; 54:915–922
7.
Wen W, Sachdev PS, Li JJ, et al: White matter hyperintensities in the forties: their prevalence and topography in an epidemiological sample aged 44–48. Hum Brain Mapp 2009; 30:1155–1167
8.
Taylor WD: Clinical practice: depression in the elderly. N Engl J Med 2014; 371:1228–1236
9.
Aizenstein HJ, Baskys A, Boldrini M, et al: Vascular depression consensus report: a critical update. BMC Med 2016; 14:161
10.
González HM, Tarraf W, Whitfield K, et al: Vascular depression prevalence and epidemiology in the United States. J Psychiatr Res 2012; 46:456–461
11.
Park JH, Lee SB, Lee JJ, et al: Epidemiology of MRI-defined vascular depression: a longitudinal, community-based study in Korean elders. J Affect Disord 2015; 180:200–206
12.
Alexopoulos GS, Raue PJ, Kiosses DN, et al: Comparing Engage with PST in late-life major depression: a preliminary report. Am J Geriatr Psychiatry 2015; 23:506–513
13.
Gustavson KA, Alexopoulos GS, Niu GC, et al: Problem-solving therapy reduces suicidal ideation in depressed older adults with executive dysfunction. Am J Geriatr Psychiatry 2016; 24:11–17
14.
Ho CSh, Jin A, Nyunt MSZ, et al: Mortality rates in major and subthreshold depression: 10-year follow-up of a Singaporean population cohort of older adults. Postgrad Med 2016; 128:642–647
15.
Alexopoulos GS, Kiosses DN, Klimstra S, et al: Clinical presentation of the “depression-executive dysfunction syndrome” of late life. Am J Geriatr Psychiatry 2002; 10:98–106
16.
Diniz BS, Butters MA, Albert SM, et al: Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br J Psychiatry 2013; 202:329–335
17.
Steffens DC, Potter GG, McQuoid DR, et al: Longitudinal magnetic resonance imaging vascular changes, apolipoprotein E genotype, and development of dementia in the Neurocognitive Outcomes of Depression in the Elderly Study. Am J Geriatr Psychiatry 2007; 15:839–849
18.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed, DSM-5. Washington, DC, American Psychiatric Association, 2013
19.
Potter GG, McQuoid DR, Steffens DC, et al: Neuropsychological correlates of magnetic resonance imaging–defined subcortical ischemic depression. Int J Geriatr Psychiatry 2009; 24:219–225
20.
Taylor WD, Aizenstein HJ, Alexopoulos GS: The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry 2013; 18:963–974
21.
Case A, Deaton A: Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci USA 2015; 112:15078–15083
22.
Case A, Deaton A: Mortality and morbidity in the 21st century. Brookings Pap Econ Act 2017 (spring):397–476
23.
McCarthy JF, Bossarte RM, Katz IR, et al: Predictive modeling and concentration of the risk of suicide: implications for preventive interventions in the US Department of Veterans Affairs. Am J Public Health 2015; 105:1935–1942
24.
Kaplan MS, McFarland BH, Huguet N, et al: Suicide risk and precipitating circumstances among young, middle-aged, and older male veterans. Am J Public Health 2012; 102(suppl 1):S131–S137
25.
Choi NG, DiNitto DM, Marti CN, et al: Physical health problems as a late-life suicide precipitant: examination of coroner/medical examiner and law enforcement reports. Gerontologist (Epub ahead of print, Sept 18, 2017)
26.
Paulson D, Lichtenberg PA: Vascular depression and frailty: a compound threat to longevity among older-old women. Aging Ment Health 2013; 17:901–910
27.
Almeida OP, Hankey GJ, Yeap BB, et al: Depression, frailty, and all-cause mortality: a cohort study of men older than 75 years. J Am Med Dir Assoc 2015; 16:296–300
28.
Sheline YI, Pieper CF, Barch DM, et al: Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry 2010; 67:277–285
29.
Boldrini M, Santiago AN, Hen R, et al: Hippocampal granule neuron number and dentate gyrus volume in antidepressant-treated and untreated major depression. Neuropsychopharmacology 2013; 38:1068–1077
30.
Taler M, Miron O, Gil-Ad I, et al: Neuroprotective and procognitive effects of sertraline: in vitro and in vivo studies. Neurosci Lett 2013; 550:93–97
31.
Sheline YI, West T, Yarasheski K, et al: An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. Sci Transl Med 2014; 6:236re4
32.
Pan Z, Grovu RC, Cha DS, et al: Pharmacological treatment of cognitive symptoms in major depressive disorder. CNS Neurol Disord Drug Targets 2017; 16:891–899
33.
Sanchez C, Asin KE, Artigas F: Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 2015; 145:43–57
34.
Mahableshwarkar AR, Zajecka J, Jacobson W, et al: A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 2015; 40:2025–2037
35.
McIntyre RS, Lophaven S, Olsen CK: A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014; 17:1557–1567
36.
Kay DB, Dombrovski AY, Buysse DJ, et al: Insomnia is associated with suicide attempt in middle-aged and older adults with depression. Int Psychogeriatr 2016; 28:613–619
37.
Bernert RA, Turvey CL, Conwell Y, et al: Association of poor subjective sleep quality with risk for death by suicide during a 10-year period: a longitudinal, population-based study of late life. JAMA Psychiatry 2014; 71:1129–1137
38.
Alghamdi BS: The neuroprotective role of melatonin in neurological disorders. J Neurosci Res 2018; 96:1136–1149
39.
Vural EMS, van Munster BC, de Rooij SE: Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature. Drugs Aging 2014; 31:441–451
40.
Morin CM, Culbert JP, Schwartz SM: Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994; 151:1172–1180
41.
Geiger-Brown JM, Rogers VE, Liu W, et al: Cognitive behavioral therapy in persons with comorbid insomnia: a meta-analysis. Sleep Med Rev 2015; 23:54–67
42.
Kiosses DN, Alexopoulos GS: Problem-solving therapy in the elderly. Curr Treat Options Psychiatry 2014; 1:15–26
43.
Kiosses DN, Arean PA, Teri L, et al: Home-delivered problem adaptation therapy (PATH) for depressed, cognitively impaired, disabled elders: a preliminary study. Am J Geriatr Psychiatry 2010; 18:988–998
44.
Jorge RE, Moser DJ, Acion L, et al: Treatment of vascular depression using repetitive transcranial magnetic stimulation. Arch Gen Psychiatry 2008; 65:268–276
45.
Meyer JP, Swetter SK, Kellner CH: Electroconvulsive therapy in geriatric psychiatry: a selective review. Psychiatr Clin North Am 2018; 41:79–93
46.
Spaans H-P, Kok RM, Bouckaert F, et al: Vascular risk factors in older patients with depression: outcome of electroconvulsive therapy versus medication. Int J Geriatr Psychiatry 2018; 33:371–378
Information & Authors
Information
Published In
History
Received: 16 May 2018
Revision received: 27 June 2018
Accepted: 16 July 2018
Published online: 1 December 2018
Published in print: December 01, 2018
Keywords
Authors
Funding Information
National Institute of Mental Health10.13039/100000025: R01 MH102246 PI: Taylor
Supported by NIMH grant R01 MH102246.The authors report no financial relationships with commercial interests.Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).